Key result
Preclinical animal studies indicate that both prothrombin complex concentrates and specific reversal agents effectively reverse DOAC anticoagulation and have the potential for clinical use.
Why the study?
Do DOAC reversal strategies (PCCs or specific antidotes) reduce bleeding and restore coagulation in animal models of DOAC anticoagulation?
Population
26 preclinical animal studies investigating the reversal of direct oral anticoagulants.
Comparison
DOAC reversal strategies including prothrombin… vs Control/vehicle or alternative reversal…
Design
Review
Authors
Loading...
Caution against adopting PCCs or specific agents for DOAC reversal from animal data alone; leaves open need for clinical trials.
Do DOAC reversal strategies (PCCs or specific antidotes) reduce bleeding and restore coagulation in animal models of DOAC anticoagulation?
Preclinical animal models demonstrate that both prothrombin complex concentrates and specific antidotes can effectively reverse DOAC-induced anticoagulation and reduce bleeding.
Honickel et al. (2017) conducted a review in DOAC anticoagulation-related bleeding (n=26). DOAC reversal agents (PCCs and specific antidotes) was evaluated on Reversal of DOAC anticoagulation (bleeding volume and time). Preclinical animal studies indicate that both prothrombin complex concentrates and specific reversal agents effectively reverse DOAC anticoagulation and have the potential for clinical use.